Placeholder Banner

BIO Comments on FDA Guidance: Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cells Products

June 10, 2022

On Friday, June 10th, BIO submitted comments in response to the FDA’s draft guidance on Chimeric antigen receptor (CAR) T cell products (i.e., human gene therapy products in which the T cell specificity is genetically modified to enable recognition of a desired target antigen for therapeutic purposes). In the comments submitted, BIO expressed appreciation for the FDA’s statement that recommendations in the guidance will be applicable to other genetically modified lymphocytes. However, as the title of the guidance is limited to (CAR) T cells and there is little mention of therapies beyond (CAR) T, BIO raised the need for additional clarity on which principles within the guidance the Agency plans to apply more broadly. To that end, BIO urged FDA to expand the scope of the guidance and provide further detail on the breadth of products the guidance would apply to, especially given the unique scientific considerations presented by certain cell types. Finally, in addition to a number of specific line edits, BIO highlighted that the landscape of regenerative medicines is continually expanding and evolving and there are a number of topics where sponsors could benefit from the issuance of additional guidances. 

Download Full Comments Below
BIO Comment Letter (CAR) T Cell Products Guidance
Discover More
On October 28th, BIO submitted comments to the World Health Organization on its new draft guideline containing regulatory considerations and requirements for the marketing authorization of monoclonal antibodies (mAbs) and related products based on…
On November 1st, BIO submitted comments in response to the Food & Drug Administration’s (FDA) recent Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. The meeting was primarily focused on two topics: the future of the…
On Friday, September 23rd, BIO submitted comments in response to a new draft guidance describing FDA’s perspective on its use of remote regulatory assessments (RRAs). In particular, the draft guidance responded to frequently asked questions on what…